Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $0.28 (2024)

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s share price gapped up before the market opened on Monday . The stock had previously closed at $0.28, but opened at $0.29. Ginkgo Bioworks shares last traded at $0.29, with a volume of 2,576,757 shares changing hands.

Analysts Set New Price Targets

Several research firms have recently weighed in on DNA. The Goldman Sachs Group lowered their price objective on shares of Ginkgo Bioworks from $0.80 to $0.30 and set a "sell" rating on the stock in a research report on Tuesday, July 9th. William Blair lowered shares of Ginkgo Bioworks from a "market perform" rating to an "underperform" rating in a report on Friday, May 10th. Morgan Stanley reduced their target price on shares of Ginkgo Bioworks from $2.00 to $1.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 15th. Finally, BTIG Research reduced their target price on shares of Ginkgo Bioworks from $0.50 to $0.20 and set a "sell" rating on the stock in a report on Wednesday, June 26th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, Ginkgo Bioworks presently has a consensus rating of "Hold" and an average price target of $1.40.

Check Out Our Latest Report on DNA

Ginkgo Bioworks Stock Performance

The company's fifty day moving average is $0.48 and its 200 day moving average is $0.93. The company has a market cap of $619.16 million, a P/E ratio of -0.64 and a beta of 1.14.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). The business had revenue of $37.94 million for the quarter, compared to analyst estimates of $45.50 million. Ginkgo Bioworks had a negative net margin of 409.11% and a negative return on equity of 56.09%. During the same quarter last year, the firm earned ($0.08) EPS. Analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.3 EPS for the current year.

Ad Monetary GoldBiden Pushing To Replace The Dollar With a Digital Coin, Control Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs).If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late.

Insiders Place Their Bets

In related news, Director Harry Sloan bought 297,619 shares of the business's stock in a transaction dated Tuesday, May 14th. The shares were purchased at an average price of $0.91 per share, with a total value of $270,833.29. Following the purchase, the director now owns 718,540 shares of the company's stock, valued at approximately $653,871.40. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In other Ginkgo Bioworks news, Director Harry Sloan purchased 297,619 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average cost of $0.91 per share, with a total value of $270,833.29. Following the transaction, the director now directly owns 718,540 shares in the company, valued at approximately $653,871.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Marijn E. Dekkers sold 265,000 shares of Ginkgo Bioworks stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $0.83, for a total transaction of $219,950.00. Following the transaction, the director now directly owns 5,515,364 shares of the company's stock, valued at $4,577,752.12. The disclosure for this sale can be found here. Insiders have sold a total of 339,766 shares of company stock valued at $271,961 in the last quarter. Insiders own 15.05% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Salem Investment Counselors Inc. raised its holdings in Ginkgo Bioworks by 110.6% in the first quarter. Salem Investment Counselors Inc. now owns 4,758,585 shares of the company's stock worth $5,520,000 after buying an additional 2,499,425 shares during the last quarter. Norges Bank purchased a new position in Ginkgo Bioworks in the fourth quarter worth about $24,967,000. Vanguard Group Inc. raised its holdings in Ginkgo Bioworks by 3.1% in the third quarter. Vanguard Group Inc. now owns 132,316,999 shares of the company's stock worth $239,494,000 after buying an additional 4,016,221 shares during the last quarter. Pinebridge Investments L.P. raised its holdings in Ginkgo Bioworks by 358.2% in the fourth quarter. Pinebridge Investments L.P. now owns 140,935 shares of the company's stock worth $238,000 after buying an additional 110,177 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. raised its holdings in Ginkgo Bioworks by 79.2% in the third quarter. B. Riley Wealth Advisors Inc. now owns 115,803 shares of the company's stock worth $210,000 after buying an additional 51,170 shares during the last quarter. 78.63% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Company Profile

(Get Free Report)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

Further Reading

  • Five stocks we like better than Ginkgo Bioworks
  • 3 Ways To Invest In Coffee, Other Than Drinking It
  • Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
  • Best ESG Stocks: 11 Best Stocks for ESG Investing
  • Has This Leading Tech Stock Halted the AI Surge?
  • How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
  • Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes

→ Jeff Bezos’s Terrifying New Technology (From InvestorPlace) (Ad)Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $0.28 (3)

Should you invest $1,000 in Ginkgo Bioworks right now?

Before you consider Ginkgo Bioworks, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.

While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $0.28 (4)

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $0.28 (2024)

FAQs

Will DNA stock go back up? ›

DNA Stock 12 Month Forecast

Based on 5 Wall Street analysts offering 12 month price targets for Ginkgo Bioworks Holdings in the last 3 months. The average price target is $0.44 with a high forecast of $1.00 and a low forecast of $0.20. The average price target represents a 57.14% change from the last price of $0.28.

What are the predictions for Ginkgo Bioworks? ›

Ginkgo Bioworks Holdings Stock Forecast

The 5 analysts with 12-month price forecasts for DNA stock have an average target of 1.40, with a low estimate of 0.20 and a high estimate of 3.00. The average target predicts an increase of 389.34% from the current stock price of 0.29.

What is Ginkgo Bioworks forecast for 2024? ›

According to our current DNA stock forecast, the value of Ginkgo Bioworks Holdings, Inc. shares will rise by 13.82% and reach $ 0.374916 per share by July 23, 2024. Per our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).

Is DNA stock a buy or sell? ›

DNA Signals & Forecast

The Ginkgo Bioworks stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.

Is Ginkgo Bioworks in trouble? ›

Ginkgo Bioworks incurred a net earnings loss of $165.911 in 2024's first quarter. On top of that, and perhaps worst of all, Ginkgo Bioworks might get delisted from the New York Stock Exchange. The NYSE warned/threatened Ginkgo Bioworks because the company's share price stayed below $1 for 30 consecutive trading days.

Where will Ginkgo Bioworks be in 5 years? ›

Over the next five years, I don't expect a big turnaround in the business. While Ginkgo's revenue will grow, its costs are sure to increase as well. Simply locking in and securing more deals is not enough to expect that the business will be in a better place five years from now.

Did Bill Gates invest in Ginkgo Bioworks? ›

Ginkgo Bioworks Is Now a Unicorn

In 2014, Ginkgo was the first biotech company to ever be accepted by Y Combinator—a now renown Silicon Valley venture capital “seed accelerator.” Since then, Ginkgo has raised $429 million, which includes $275 million in funding from Bill Gates' Cascade Investment and others.

Does Cathie Wood own DNA stock? ›

Ginkgo Bioworks

29 alone, Cathie Wood has been an enthusiastic buyer of shares in Ginkgo Bioworks Holdings (NYSE: DNA). It's no surprise what might draw her to this company as it stands to disrupt major biopharmaceutical manufacturing processes.

Is Ginkgo Bioworks a good long term investment? ›

Before you buy stock in Ginkgo Bioworks, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ginkgo Bioworks wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Who are the largest holders of Ginkgo Bioworks? ›

Shareholders: Ginkgo Bioworks Holdings, Inc.
NameEquities%
ARK Investment Management LLC 11.09 %189,606,90811.09 %
Cascade Investment LLC 8.886 %151,865,4818.886 %
Viking Global Investors LP 8.372 %143,085,1268.372 %
Baillie Gifford & Co. 7.865 %134,425,8667.865 %
1 more row

Who is backing Ginkgo Bioworks? ›

Ginkgo Bioworks will make its market debut by merging with Soaring Eagle Acquisition Corp., the blank-check company led by former MGM CEO Harry Sloan.

Who has invested in Ginkgo Bioworks? ›

Top Institutional Holders
HolderSharesDate Reported
Blackrock Inc.72.86MMar 31, 2024
Anchorage Capital Group, LLC69.85MMar 31, 2024
Sumitomo Mitsui Trust Holdings, Inc.55.87MMar 31, 2024
Nikko Asset Management Americas, Inc.55.87MMar 31, 2024
6 more rows

Is Ginkgo Bioworks stock going to reverse split? ›

Ginkgo Bioworks is likely to conduct a reverse stock split in 2024. The transaction will intentionally reduce the number of shares outstanding to boost the stock price and remain in the good graces of the NYSE.

What is Ginkgo Bioworks stock forecast for 2025? ›

Check out Ginkgo Bioworks Holdings, Inc. revenue and earnings and make informed decisions. What is DNA price target? According to analysts, DNA price target is 0.95 USD with a max estimate of 3.00 USD and a min estimate of 0.20 USD.

What is Zacks rating for Ginkgo Bioworks? ›

(Real Time Quote from BATS)
Value ScoreA
Growth ScoreA
Momentum ScoreA
VGM ScoreA

What is the future price of Ginkgo Bioworks? ›

The average one-year price target for Ginkgo Bioworks Holdings, Inc. is $1.41. The forecasts range from a low of $0.20 to a high of $3.15. A stock's price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings.

Who are the largest shareholders of DNA stock? ›

Largest shareholders include Baillie Gifford & Co, ARK Investment Management LLC, Viking Global Investors Lp, Vanguard Group Inc, ARKK - ARK Innovation ETF, BlackRock Inc., Anchorage Capital Group, L.L.C., Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., and ARKG - ARK Genomic Revolution ETF ...

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Foster Heidenreich CPA

Last Updated:

Views: 6174

Rating: 4.6 / 5 (56 voted)

Reviews: 95% of readers found this page helpful

Author information

Name: Foster Heidenreich CPA

Birthday: 1995-01-14

Address: 55021 Usha Garden, North Larisa, DE 19209

Phone: +6812240846623

Job: Corporate Healthcare Strategist

Hobby: Singing, Listening to music, Rafting, LARPing, Gardening, Quilting, Rappelling

Introduction: My name is Foster Heidenreich CPA, I am a delightful, quaint, glorious, quaint, faithful, enchanting, fine person who loves writing and wants to share my knowledge and understanding with you.